About UsNewsShop
Fighting hereditary breast and ovarian cancer
Information & Research
| More

NCT01489865

ABT-888 With Modified FOLFOX6 in Patients With Metastatic Pancreatic Cancer

Study identifier: NCT01489865
Full study details on clinicaltrials.gov

Name of PARP Inhibitor used in study:

Veliparib (Abbvie)

Eligibility:

  • Histologically proven pancreatic adenocarcinoma with measurable disease
  • any number of prior therapies except prior therapy with a PARP inhibitor
  • no brain metastases or a history of previously treated brain metastases who have been treated with surgery or stereotactic radiosurgery at least 4 weeks prior to enrollment and have a baseline MRI that shows no evidence of intracranial disease and have not had treatment with steroids within 1 week of study enrollment
  • At least 14 days must have passed since all prior anti-cancer therapy
  • At least 28 days must have passed since any prior antibody-based therapies
  • At least 28 days must have passed since any prior investigational agent

Type of study:

Phase I/II

Treatment:

  • Veliparib orally at escalating does in Phase I and then at recommended phase II dose with standard mFOLFOX-6
  • 5-FU
  • Oxaliplatin
  • Leucovorin

Study site:

Washington DC
Georgetown Lombardi Comprehensive Cancer Center
Contact: Lisa Ley, RN MSN 202-687-6653 leyl@georgetown.edu
Contact: Karen Dorsch-Vogel, RN 202-687-6974 kd252@georgetown.edu

 

Page updated 06/10/13


Disclaimer: Health links are made available for educational purposes only. This information should not be interpreted as medical advice. All health information should be discussed with your health care provider. Please read our full disclaimer for more information.

Privacy Policy | Sitemap | Contact Us

Morphtek

This site has been made possible by a generous grant from Morphotek.


Web design by Rareheron Web Design

copyright © FORCE: Facing Our Risk of Cancer Empowered, Inc.  •  info@facingourrisk.org